Karuna Therapeutics, Inc. (KRTX)
| Market Cap | 3.00B |
| Revenue (ttm) | 36.96M |
| Net Income (ttm) | -171.53M |
| Shares Out | 29.88M |
| EPS (ttm) | -4.94 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 254,413 |
| Open | 104.23 |
| Previous Close | 107.92 |
| Day's Range | 99.20 - 104.50 |
| 52-Week Range | 92.26 - 161.98 |
| Beta | 1.95 |
| Analysts | Buy |
| Price Target | 181.31 (+80.5%) |
| Earnings Date | May 5, 2022 |
About KRTX
Karuna Therapeutics, Inc., a clinical-stage biopharmaceutical company, creates and delivers transformative medicines for people living with psychiatric and neurological conditions. Its lead product candidate is KarXT, an oral modulator of muscarinic receptors that is in Phase III clinical trial for the treatment of acute psychosis in patients with schizophrenia; and for the treatment of central nervous system disorders, such as negative and cognitive symptoms of schizophrenia and psychosis, as well as for the treatment of dementia-related psych...
Financial Performance
Financial StatementsAnalyst Forecast
According to 23 analysts, the average rating for KRTX stock is "Buy." The 12-month stock price forecast is 181.31, which is an increase of 80.52% from the latest price.
News
Karuna Therapeutics to Host Virtual Event Highlighting Clinical Program for Psychosis in Alzheimer's Disease
BOSTON--(BUSINESS WIRE)--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psychiatric and...
Karuna Therapeutics (KRTX) Posts Narrower-Than-Expected Q1 Loss
Karuna Therapeutics' (KRTX) first-quarter 2022 earnings beat estimates. Due to lack of marketed products in its portfolio, KRTX did not record any revenues during the quarter.
Karuna Therapeutics Reports First Quarter 2022 Financial Results and Provides General Business Update
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics to Present at the 2022 RBC Capital Markets Global Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics to Present at Upcoming Investor Conferences
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Amid Russia's Invasion On Ukraine, Karuna Therapeutics Withdraws Guidance On Late-Stage Schizophrenia Trial
According to an SEC filing, Karuna Therapeutics Inc (NASDAQ: KRTX) is withdrawing its prior guidance for the timing of topline data for its Phase 3 EMERGENT-3 trial evaluating KarXT in schizophrenia. T...
Karuna Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides General Business Update
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics' Schizophrenia Drug Could Be a Blockbuster
Let's take a deeper dive into Karuna Therapeutics Inc. ( KRTX , Financial), which was one of the potential takeover targets I discussed last week.
Karuna Therapeutics to Present at the SVB Leerink 11th Annual Global Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
3 Can't-Miss Biotech Events Coming Up in 2022
This could be a very exciting year for these drugmakers.
Karuna Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics CEO discusses the biotech firm's drug trials for schizophrenia
Karuna Therapeutics CEO Dr. Steve Paul appeared on Wednesday's episode of "Mad Money."
Karuna Therapeutics Appoints Charmaine Lykins as Chief Commercial Officer
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Why Karuna Therapeutics Stock Tumbled This Week
Investors apparently weren't thrilled by the company's licensing agreement with Zai Lab.
Karuna Therapeutics and Zai Lab Announce Strategic Collaboration for Development, Manufacturing, and Commercializatio...
BOSTON & SHANGHAI & SAN FRANCISCO--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines f...
Karuna Therapeutics Reports Third Quarter 2021 Financial Results and Provides General Business Update
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics to Present at 2021 Virtual Wells Fargo Healthcare Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics to Present at the Citi 16th Annual BioPharma Virtual Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics Reports Second Quarter 2021 Financial Results and Provides General Business Update
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics to Present at 2021 Wedbush PacGrow Healthcare Virtual Conference
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics Announces Results from Phase 1b Trial Evaluating the Safety and Tolerability of KarXT in Healthy ...
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
Karuna Therapeutics Reports First Quarter 2021 Financial Results and Provides General Business Update
BOSTON--(BUSINESS WIRE)---- $KRTX--Karuna Therapeutics, Inc. (NASDAQ: KRTX), a clinical-stage biopharmaceutical company driven to create and deliver transformative medicines for people living with psych...
PureTech Founded Entity Karuna Therapeutics Announces Pricing of Public Offering of Common Stock
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity, Karuna Therapeutics, Inc. (NASDAQ: KRTX) announced the pricing of an underwritten public offering.